Skip to main content

Two-Year Outcomes of Surgical Treatment of Severe Ischemic Mitral Regurgitation.

Publication ,  Journal Article
Goldstein, D; Moskowitz, AJ; Gelijns, AC; Ailawadi, G; Parides, MK; Perrault, LP; Hung, JW; Voisine, P; Dagenais, F; Gillinov, AM; Thourani, V ...
Published in: N Engl J Med
January 28, 2016

BACKGROUND: In a randomized trial comparing mitral-valve repair with mitral-valve replacement in patients with severe ischemic mitral regurgitation, we found no significant difference in the left ventricular end-systolic volume index (LVESVI), survival, or adverse events at 1 year after surgery. However, patients in the repair group had significantly more recurrences of moderate or severe mitral regurgitation. We now report the 2-year outcomes of this trial. METHODS: We randomly assigned 251 patients to mitral-valve repair or replacement. Patients were followed for 2 years, and clinical and echocardiographic outcomes were assessed. RESULTS: Among surviving patients, the mean (±SD) 2-year LVESVI was 52.6±27.7 ml per square meter of body-surface area with mitral-valve repair and 60.6±39.0 ml per square meter with mitral-valve replacement (mean changes from baseline, -9.0 ml per square meter and -6.5 ml per square meter, respectively). Two-year mortality was 19.0% in the repair group and 23.2% in the replacement group (hazard ratio in the repair group, 0.79; 95% confidence interval, 0.46 to 1.35; P=0.39). The rank-based assessment of LVESVI at 2 years (incorporating deaths) showed no significant between-group difference (z score=-1.32, P=0.19). The rate of recurrence of moderate or severe mitral regurgitation over 2 years was higher in the repair group than in the replacement group (58.8% vs. 3.8%, P<0.001). There were no significant between-group differences in rates of serious adverse events and overall readmissions, but patients in the repair group had more serious adverse events related to heart failure (P=0.05) and cardiovascular readmissions (P=0.01). On the Minnesota Living with Heart Failure questionnaire, there was a trend toward greater improvement in the replacement group (P=0.07). CONCLUSIONS: In patients undergoing mitral-valve repair or replacement for severe ischemic mitral regurgitation, we observed no significant between-group difference in left ventricular reverse remodeling or survival at 2 years. Mitral regurgitation recurred more frequently in the repair group, resulting in more heart-failure-related adverse events and cardiovascular admissions. (Funded by the National Institutes of Health and Canadian Institutes of Health Research; ClinicalTrials.gov number, NCT00807040.).

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

N Engl J Med

DOI

EISSN

1533-4406

Publication Date

January 28, 2016

Volume

374

Issue

4

Start / End Page

344 / 353

Location

United States

Related Subject Headings

  • Ventricular Remodeling
  • Ventricular Function, Left
  • Treatment Failure
  • Reoperation
  • Recurrence
  • Quality of Life
  • Mitral Valve Insufficiency
  • Mitral Valve
  • Humans
  • Hospitalization
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Goldstein, D., Moskowitz, A. J., Gelijns, A. C., Ailawadi, G., Parides, M. K., Perrault, L. P., … CTSN, . (2016). Two-Year Outcomes of Surgical Treatment of Severe Ischemic Mitral Regurgitation. N Engl J Med, 374(4), 344–353. https://doi.org/10.1056/NEJMoa1512913
Goldstein, Daniel, Alan J. Moskowitz, Annetine C. Gelijns, Gorav Ailawadi, Michael K. Parides, Louis P. Perrault, Judy W. Hung, et al. “Two-Year Outcomes of Surgical Treatment of Severe Ischemic Mitral Regurgitation.N Engl J Med 374, no. 4 (January 28, 2016): 344–53. https://doi.org/10.1056/NEJMoa1512913.
Goldstein D, Moskowitz AJ, Gelijns AC, Ailawadi G, Parides MK, Perrault LP, et al. Two-Year Outcomes of Surgical Treatment of Severe Ischemic Mitral Regurgitation. N Engl J Med. 2016 Jan 28;374(4):344–53.
Goldstein, Daniel, et al. “Two-Year Outcomes of Surgical Treatment of Severe Ischemic Mitral Regurgitation.N Engl J Med, vol. 374, no. 4, Jan. 2016, pp. 344–53. Pubmed, doi:10.1056/NEJMoa1512913.
Goldstein D, Moskowitz AJ, Gelijns AC, Ailawadi G, Parides MK, Perrault LP, Hung JW, Voisine P, Dagenais F, Gillinov AM, Thourani V, Argenziano M, Gammie JS, Mack M, Demers P, Atluri P, Rose EA, O’Sullivan K, Williams DL, Bagiella E, Michler RE, Weisel RD, Miller MA, Geller NL, Taddei-Peters WC, Smith PK, Moquete E, Overbey JR, Kron IL, O’Gara PT, Acker MA, CTSN. Two-Year Outcomes of Surgical Treatment of Severe Ischemic Mitral Regurgitation. N Engl J Med. 2016 Jan 28;374(4):344–353.

Published In

N Engl J Med

DOI

EISSN

1533-4406

Publication Date

January 28, 2016

Volume

374

Issue

4

Start / End Page

344 / 353

Location

United States

Related Subject Headings

  • Ventricular Remodeling
  • Ventricular Function, Left
  • Treatment Failure
  • Reoperation
  • Recurrence
  • Quality of Life
  • Mitral Valve Insufficiency
  • Mitral Valve
  • Humans
  • Hospitalization